Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 versus second novel anti-hormonal therapy in bone-dominant metastatic castration-resistant prostate cancer
2019-000476-42Phase 4Active
- Sponsor
- Bayer Consumer Health
- Start
- Jul 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of radium-223 dichloride, enzalutamide and abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Bayer Consumer Health. Primary endpoint: Overall survival. Started Jul 2020; status: active.
02
Drugs
radium-223 dichlorideenzalutamideabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2019-000476-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000476-42.